ArticlemBio2026
Identification and characterization of non-canonical azole antifungal resistance pathways in
Endrews Delbaje, Matheus Mertz Ribeiro, Ricardo de Oliveira Barbosa Bitencourt, Katrien Lagrou, Vit Hubka, Laís Pontes, Angélica Zaninelli Schreiber, Nicole Robbins, Leah E Cowen, Thaila Fernanda Dos Reis and 1 more
Abstract read
In one paragraphArticle in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Endrews DelbajeDepartamento de Biologia, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirao Preto, São Paulo, Brazil.ORCID 0000-0002-0313-9046 Matheus Mertz RibeiroFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirao Preto, São Paulo, Brazil.
Ricardo de Oliveira Barbosa BitencourtFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirao Preto, São Paulo, Brazil.
Katrien LagrouDepartment of Laboratory Medicine, National Reference Centre for Mycosis, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0001-8668-1350 Vit HubkaDepartment of Genetics and Microbiology, Faculty of Science, Charles University, Prague, Czech Republic.
Laís PontesSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Angélica Zaninelli SchreiberSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Nicole RobbinsDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Thaila Fernanda Dos ReisDepartamento de Bioquímica, Instituto de Química, Universidade Estadual de São Paulo, Araraquara, Brazil.
Gustavo H GoldmanDepartamento de Biologia, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirao Preto, São Paulo, Brazil.ORCID 0000-0002-2986-350X Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo
6 · The paper itselfAbstract
Human fungal infections, especially those caused by IMPORTANCE: Azole antifungals are the frontline therapy for infections caused by the opportunistic mold
Indexed as
Antifungal AgentsAspergillus fumigatusAzolesDrug Resistance, FungalAspergillosisCytochrome P-450 Enzyme SystemFungal ProteinsGene Expression ProfilingGenetic VariationHumansMicrobial Sensitivity TestsMutationWhole Genome SequencingAntifungal AgentsAzolescytochrome P-450 CYP51A, AspergillusCytochrome P-450 Enzyme SystemFungal ProteinsAspergillus fumigatusazole resistanceCyp51evolutionnoncanonical Cyp51 resistance
Identifiers
PMID42615624
PMCPMC13556210
What OpenQuestion holds
Textmetadata
Read underepoch 390